Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
| Revenue (TTM) | $450.89M |
| Gross Profit (TTM) | $338.28M |
| EBITDA | $-32.11M |
| Operating Margin | -10.30% |
| Return on Equity | -38.60% |
| Return on Assets | -4.25% |
| Revenue/Share (TTM) | $1.84 |
| Book Value | $0.60 |
| Price-to-Book | 6.45 |
| Price-to-Sales (TTM) | 2.16 |
| EV/Revenue | 2.073 |
| EV/EBITDA | 130.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.80% |
| Shares Outstanding | $258.19M |
| Float | $210.66M |
| % Insiders | 3.17% |
| % Institutions | 73.42% |
Volatility is currently contracting
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:
Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations
ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and a loss of approximately $(0.07) per share -- both below consensus estimates.
Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m.
ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARDX and any ticker you trade — then tracks every position and per-strategy win rate.
